AI Article Synopsis
- Recent research and innovative strategies are being implemented to discover and create new drugs for tuberculosis, a major global health challenge.
- Approximately nine million new tuberculosis cases occur annually, with nearly two million deaths, highlighting the urgent need for new antitubercular medications.
- The current discussion includes the status of tuberculosis, advancements in drug development, new molecular targets, novel agents in various development stages, and efforts to create new lead compounds with different pharmacophores.
Article Abstract
Recent developments and novel research strategies are adopted widely to discover and develop the new drugs to treat tuberculosis. New antitubercular drugs are urgently needed because tuberculosis remains a global health problem as around nine million new cases are estimated each year with almost two million fatalities. It states the impact and outcomes that have made a significant effect in antitubercular drug development. We are presenting current status of tuberculosis, antitubercular drug development, novel molecular targets, novel agents in clinical and pre-clinical development and some efforts that are being made in the development of novel molecules based on different pharmacophores as lead compounds and recent strategies.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.2174/13895575113139990076 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Machine learning-enabled virtual screening indicates the anti-tuberculosis activity of aldoxorubicin and quarfloxin with verification by molecular docking, molecular dynamics simulations, and biological evaluations.
Brief Bioinform
November 2024
Institute of Medical Information, Chinese Academy of Medical Sciences and Peking Union Medical College, Chaoyang District, Beijing 100020, China.
Drug resistance in Mycobacterium tuberculosis (Mtb) is a significant challenge in the control and treatment of tuberculosis, making efforts to combat the spread of this global health burden more difficult. To accelerate anti-tuberculosis drug discovery, repurposing clinically approved or investigational drugs for the treatment of tuberculosis by computational methods has become an attractive strategy. In this study, we developed a virtual screening workflow that combines multiple machine learning and deep learning models, and 11 576 compounds extracted from the DrugBank database were screened against Mtb.
View Article and Find Full Text PDFEvaluation of susceptibility to pyrazinamide and streptomycin, isoniazid, rifampin and ethambutol of Mycobacterium caprae strains isolated from European bison (Bison bonasus caucasicus) in the Bieszczady Mountains (Southern Poland).
Pol J Vet Sci
September 2024
Department of Food Hygiene and Public Health Protection, Institute of Veterinary Medicine, Warsaw University of Life Sciences (SGGW), Nowoursynowska 159, 02-776 Warsaw, Poland.
The material for drug resistance testing was 28 strains of Mycobacterium caprae isolated from tissue collected post mortem from a free-living Bieszczady Mountain European bison (Bison bonasus caucasicus) herd. All drug susceptibility tests were carried out on an automated Bactec mycobacterial growth indicator tube (MGIT) 960 system, using Bactec MGIT 960 streptomycin, isoniazid, rifampin and ethambutol (S.I.
View Article and Find Full Text PDFIsolated Prostate Tuberculosis Mimicking Prostate Cancer.
Ethiop J Health Sci
October 2024
Department of Pathology, Addis Ababa University, College of Health Sciences, Addis Ababa, Ethiopia.
Background: Tuberculosis (TB) remains the deadliest infectious disease globally, with the kidneys being the most frequently affected organ in the genitourinary system. Isolated prostate involvement by tuberculosis is rare and may mimic prostate cancer. This case report aims to highlight the diagnostic challenges and therapeutic responses associated with isolated prostate tuberculosis, particularly in the context of significantly elevated prostate-specific antigen (PSA) levels in a TB-endemic region.
View Article and Find Full Text PDFIn silico study of bioactive compounds derived from Indonesian marine invertebrates as a novel antituberculosis agent.
Turk J Med Sci
December 2024
Research Center for Vaccine and Drugs, Research Organization for Health, National Research and Innovation Agency (BRIN), Cibinong, Bogor, Indonesia.
Background/aim: Tuberculosis (TB) has become the world's deadliest disease. The lack of an effective therapeutic drug to treat it is one of the obstacle for doctors. Today, multidrug-resistant TB cases are increasing.
View Article and Find Full Text PDFDesign, synthesis and biological evaluation of ethyl 5-(1-benzyl-1H-indol-5-yl)isoxazole-3-carboxylates as antimycobacterial agents.
ChemMedChem
December 2024
NIPER Hyderabad: National Institute of Pharmaceutical Education and Research Hyderabad, Chemical Sciences, Balanagar, 500037, Hyderabad, INDIA.
The continued prevalence of drug-resistant Mycobacterium tuberculosis (Mtb) strains, particularly against first-line antitubercular (anti-TB) drugs, presents an impending public health threat that necessitates the exploration and development of New Chemical Entities (NCEs). In search of new anti-TB leads, a library of ethyl 5-(1-benzyl-1H-indol-5-yl)isoxazole-3-carboxylates were generated through a strategy of scaffold hopping from the proven isoxazole-3-carboxylate-based anti-TB pharmacophore. We evaluated their antibacterial potential against a panel of pathogenic bacteria and MtbH37Rv strains.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!